Ofatumumab

Related by string. ofatumumab * * ofatumumab HuMax CD# . Arzerra ofatumumab *

Related by context. All words. (Click for frequent words.) 75 Epratuzumab 74 PEGylated Fab fragment 72 Meets Primary Endpoint 72 Belimumab 72 Dasatinib 72 Dapagliflozin 72 Pivotal Study 72 Golimumab 72 Sapacitabine 71 Phase IIb Trial 71 Blinatumomab 71 Phase 2b Clinical Trial 71 Vicriviroc 71 Bortezomib 71 Hsp# Inhibitor 71 Adalimumab 71 Alemtuzumab 70 dasatinib Sprycel ® 70 sodium glucose cotransporter 70 Elesclomol 70 Trial Evaluating 70 Bevacizumab 70 Phase IIb Clinical Trial 70 investigational humanized monoclonal antibody 70 Voreloxin 70 Ocrelizumab 70 Diffuse Large B 70 Bosutinib 70 humanized anti 70 Phase 2b Study 70 Methylnaltrexone 70 Aflibercept 69 Personalized Immunotherapy 69 Pirfenidone 69 Elagolix 69 Rituximab 69 biologic therapy 69 Pralatrexate 69 humanized monoclonal antibody 69 JAK Inhibitor 69 oral proteasome inhibitor 69 Phase III Clinical Trial 69 Daclizumab 69 PEGylated anti 69 NDA Submission 69 Eculizumab 69 oral prodrug 69 antibody MAb 69 Relapsed Refractory 69 receptor tyrosine kinase inhibitor 69 Ozarelix 69 Irinotecan 69 Talabostat 69 Temsirolimus 69 Bucindolol 69 Tezampanel 69 Ridaforolimus 69 Clofarabine 69 Romiplostim 68 Bavituximab 68 MKC# MT 68 Romidepsin 68 Pivotal Phase III 68 Phase 2a Clinical Trial 68 Tofacitinib 68 Phase III Trial 68 Dupuytren Contracture 68 Preclinical Data 68 Initiate Phase 68 FOLOTYN ® 68 JAK2 Inhibitor 68 Decitabine 68 Investigational Compound 68 Pradefovir 68 Pazopanib 68 MEK Inhibitor 68 MAGE A3 ASCI 68 Aurora Kinase 68 FDA Accepts 68 Cutaneous T 68 Pivotal Trial 68 Monoclonal Antibody 68 Lubiprostone 68 Perifosine 68 Maribavir 68 multi kinase inhibitor 68 Clinical Trial Results 68 vapreotide acetate 68 Vandetanib 68 Phase 2b Trial 68 LymphoStat B belimumab 68 Oral Fingolimod 68 XYOTAX TM 67 Initiates Clinical 67 Ustekinumab 67 Phase 2a Trial 67 Tocilizumab 67 TNF Tumor Necrosis Factor 67 Hormone Refractory Prostate Cancer 67 Pixantrone 67 ADP receptor antagonist 67 Elotuzumab 67 TBC# 67 Tyrosine Kinase Inhibitor 67 Traficet EN 67 generation purine nucleoside 67 Monotherapy 67 Ceflatonin 67 Drug Candidate 67 Investigational Treatment 67 Completes Patient Enrollment 67 Safinamide 67 Denufosol 67 Gleevec resistant 67 Successfully Completes Phase 67 Archexin 67 Pathway Inhibitor 67 leukemia CLL 67 PNP inhibitor 67 peripherally acting 67 Glatiramer Acetate 67 Cetrorelix 67 targeting CD# 67 selective phosphodiesterase 67 oral dihydropyrimidine dehydrogenase DPD 67 LHRH antagonist 67 Cethromycin 67 beta 1a 67 Pertuzumab 67 Pharmacokinetic Study 67 HuMax EGFr 67 chimeric monoclonal antibody 67 Dose Escalation 67 Adjuvant Treatment 67 Mipomersen 67 SPRYCEL ® 67 Amrubicin 67 Antitumor Activity 67 selective modulator 67 erlotinib Tarceva ® 67 Anti Tumor Activity 67 Investigational Agent 67 Iloperidone 67 Luteinizing Hormone Releasing Hormone 67 Previously Treated 67 mGluR5 NAM 67 HuMax CD# 67 proteasome inhibitor 67 Omacetaxine 67 Chronic Lymphocytic Leukemia 67 MKC# MKC# PP 67 II Clinical Trial 67 KRN# 67 CYC# 67 Pivotal Phase 67 Simulect 67 Complicated Skin 67 Tesetaxel 67 Ambrisentan 67 refractory chronic lymphocytic 66 Oral Calcitonin 66 Malignant Melanoma 66 dasatinib Sprycel 66 CYT# potent vascular disrupting 66 Silodosin 66 Nilotinib 66 Nexavar ® 66 Etanercept 66 Glufosfamide 66 non nucleoside inhibitor 66 Palifosfamide 66 Randomized Phase 66 Dalbavancin 66 Boceprevir 66 Melphalan 66 Panzem R 66 polymerase inhibitor 66 Ranolazine 66 sorafenib tablets 66 Patient Enrollment 66 Laquinimod 66 Lenalidomide 66 mertansine 66 Peginterferon alfa 2b 66 imatinib Gleevec ® 66 Pafuramidine 66 Chronic Lymphocytic Leukemia CLL 66 Darunavir 66 Tanespimycin 66 Files IND 66 Phase 1b Clinical Trial 66 First Patient Dosed 66 docetaxel Taxotere ® 66 Metastatic Colorectal Cancer 66 GW# [003] 66 histone deacetylase HDAC inhibitor 66 Pemetrexed 66 Interferon alpha 66 IgG1 monoclonal antibody 66 Roflumilast 66 PDE4 inhibitor 66 Aliskiren 66 Humanized Anti 66 mTOR inhibitor 66 Pegloticase 66 Epidermal Growth Factor Receptor 66 relapsing multiple sclerosis 66 Novel Oral 66 BRIM2 66 Tumor Necrosis Factor 66 investigational monoclonal antibody 66 Pharmacokinetics PK 66 icatibant 66 selective A2A adenosine receptor 66 Receives Orphan Drug Designation 66 Ixabepilone 66 Clinical Trial Evaluating 66 Eltrombopag 66 Granted Orphan Drug 66 JAK inhibitor 66 Initiates Phase 66 Milatuzumab 66 Anti TNF 66 pseudobulbar affect PBA 66 HuMax CD4 66 Clevudine 66 Fludarabine 66 Initiates Enrollment 66 Everolimus 66 Rigel R# 66 Receptor Agonist 66 CD# monoclonal antibody 66 Carfilzomib 66 BCR ABL inhibitors 66 Advanced Renal Cell 66 Degarelix 66 AEG# 66 huC# DM4 66 Severe Sepsis 66 Dacetuzumab 66 phase IIb clinical 66 Zenvia Phase III 66 Phase IIa Clinical Trial 66 administered concomitantly 66 adalimumab Humira 66 Chronic Myeloid Leukemia 66 Previously Untreated 66 Lupus Nephritis 66 IL# PE#QQR 66 mild vasodilator 66 Sipuleucel T 66 TKB# 65 sunitinib Sutent ® 65 developing Bicifadine serotonin 65 acyclovir Lauriad R 65 Ciclesonide 65 Shows Efficacy 65 Prolongs Survival 65 Enzyme Replacement Therapy 65 Phase III Trials 65 Tamibarotene 65 relapsed leukemia 65 Initiates Phase III 65 XL# anticancer compounds 65 Anti CD# Antibody 65 investigational oral inhibitor 65 Metastatic Melanoma 65 BCR ABL inhibitor 65 Receptor Antagonist 65 CCR5 antagonist 65 small molecule Hedgehog 65 HGS ETR1 65 Vidofludimus 65 Hematological Malignancies 65 somatostatin analogue 65 soluble tumor necrosis 65 R roscovitine 65 Fingolimod 65 Patients Treated With 65 oral dual endothelin 65 Phase Ib IIa 65 Nimotuzumab 65 TYZEKA 65 Initiate Clinical Trial 65 Reovirus 65 Sym# 65 MyVax R 65 Ceftobiprole 65 Randomized Phase II 65 Pulmonary Arterial Hypertension 65 HCV Protease Inhibitor 65 leukemia AML 65 dyskinesia PD LID 65 Initiates Phase II 65 Universal Flu Vaccine 65 Imatinib 65 small molecule thrombopoietin 65 AVASTIN 65 Docetaxel 65 ospemifene 65 Anti Tumor 65 PKC# 65 Kit CD# positive 65 reslizumab 65 orally administered inhibitor 65 Panitumumab 65 Peginterferon 65 SAR# [004] 65 immunotherapeutic agent 65 RhuDex 65 Study Evaluating 65 selective androgen receptor modulator 65 Prostate Cancer Vaccine 65 TREANDA 65 Dose Ranging Study 65 HCD# [002] 65 Nitazoxanide 65 First Patient Enrolled 65 Plicera 65 RhuDex ® 65 YONDELIS 65 familial amyloidotic polyneuropathy FAP 65 UPLYSO 65 systemic juvenile idiopathic 65 Liprotamase 65 mGluR2 positive 65 Factor VIIa 65 Tasigna nilotinib 65 gastrointestinal stromal tumors GIST 65 mGluR5 negative 65 Oral Cladribine 65 Apixaban 65 Panzem R NCD 65 RNAi Therapeutic 65 Apaziquone 65 Randomized Double blind 65 nucleoside analog 65 Multiple Ascending Dose 65 Phase III Pivotal 65 MT#/MEDI-# 65 Initiate Phase III 65 Presents Positive 65 STELARA TM 65 Presents Preclinical Data 65 Investigational Drug 65 Treatment Experienced 65 cetuximab Erbitux R 65 Gemcitabine 65 Thiarabine 65 Pegylated 65 VEGFR2 inhibitor 65 rilonacept 65 Elvitegravir 65 Combination REOLYSIN R 65 Soft Tissue Sarcoma 65 virus HCV protease inhibitor 65 Ganciclovir 65 GATTEX TM 65 treat benign prostatic 65 visilizumab 65 humanized monoclonal 65 Iluvien ® 65 tyrosine kinase inhibitor 65 Advanced Melanoma 64 Linaclotide 64 alfa 2a 64 Rivaroxaban 64 TORISEL 64 Long Term Efficacy 64 Rilonacept 64 Inhalation Aerosol 64 hypereosinophilic syndrome 64 Targeted Therapy 64 aripiprazole Abilify 64 Bendamustine 64 chronic eosinophilic leukemia 64 Recombinant Human 64 Refractory Hodgkin Lymphoma 64 Fabry Disease 64 Efficacy Trial 64 Brentuximab Vedotin SGN 64 interferon gamma 1b 64 cell lymphoma CTCL 64 fosbretabulin 64 peptidic compound 64 myelofibrosis polycythemia vera 64 Myelodysplastic Syndromes 64 pan HDAC inhibitor 64 TRX1 64 vidofludimus 64 Patient Enrolment 64 HDAC Inhibitor 64 Receptor Antagonists 64 nucleoside reverse transcriptase inhibitor 64 Lung Cancer Drug 64 Liposomal 64 cathepsin K inhibitor 64 Pooled Analysis 64 Chronic Hepatitis C 64 dependent kinase inhibitor 64 administered subcutaneously 64 liposomal formulation 64 methylnaltrexone bromide 64 Kinase Inhibitor 64 pegylated interferon alfa 2a 64 indolent NHL 64 ofatumumab HuMax CD# 64 OMP #R# 64 Saxagliptin 64 diarrhea predominant irritable 64 etanercept Enbrel 64 topical gel formulation 64 CD# CEA 64 Receives Orphan Drug 64 angiogenesis inhibitor 64 PEG SN# 64 evaluating tivozanib 64 Protease Inhibitor 64 allosteric modulator NAM 64 Valopicitabine 64 Vidaza azacitidine 64 Anidulafungin 64 DORIBAX 64 Tasimelteon 64 Albuferon TM 64 oral Janus kinase 64 Demonstrates Positive 64 Xanafide 64 NOXAFIL 64 5 Fluorouracil 64 BiTE R 64 AAG geldanamycin analog 64 Aztreonam 64 Erlotinib 64 milatuzumab 64 Enzastaurin 64 PEGylated interferon beta 1a 64 Antiviral Activity 64 Ecallantide 64 Tesamorelin 64 castrate resistant prostate cancer 64 VitiGam 64 Genasense ® 64 nucleoside analogue 64 Oral Spray 64 Chemokine Receptor 64 Maraviroc 64 Well Tolerated 64 systemic lupus erythematosus SLE 64 Arimoclomol 64 xanthine oxidase inhibitor 64 Relapsed Refractory Aggressive 64 CD4 monoclonal antibody 64 IMA# 64 Ceftaroline 64 VIVITROL ® 64 Improved Survival 64 Improves Survival 64 CIMZIA TM 64 ALN TTR 64 Myelofibrosis 64 selective orally bioavailable 64 Amigal 64 drug pipeline TAFA# 64 6R BH4 64 Gout Drug 64 Entereg R 64 Disease Progression 64 CHOP chemotherapy 64 intravesical infusion therapy 64 INSPIRE Trial Phase III 64 Rheumatoid Arthritis Drug 64 Plaque Psoriasis 64 canakinumab 64 Renal Cell Carcinoma 64 ALVESCO R 64 HGS ETR2 64 pralatrexate injection folate analogue 64 CCX# B 64 Vaccine Adjuvant 64 metastatic malignant 64 Pimavanserin 64 Abatacept 64 cetuximab Erbitux ® 64 Paclitaxel Carboplatin 64 Mylan Receives Approval 64 registrational trial 64 Rheumatoid Arthritis RA 64 novel topoisomerase 64 lumiliximab 64 investigational compound 64 Relapsing Remitting Multiple Sclerosis 64 RhuDex R 64 Antibody Drug Conjugate 64 Completes Enrollment 64 mapatumumab 64 VEGF inhibitors 64 Alfimeprase 64 Confirmatory Phase 64 IMC A# 64 erlotinib Tarceva R 64 Eniluracil 64 Ziprasidone 64 radiation sensitizer 64 EGFr 64 Bezielle 63 Treatment Naive Patients 63 Annamycin 63 Novel Antibiotic 63 delta opioid receptor 63 Preclinical Models 63 Demonstrates Efficacy 63 Loxapine 63 Diabetic Macular Edema 63 NVA# 63 Orally administered 63 Single Dose 63 Dose Escalation Study 63 pediatric Crohn disease 63 tiapamil 63 IAP inhibitors 63 Infected Patients 63 Trastuzumab 63 Remission Maintenance 63 #D#C# 63 Tumour Vascular Disrupting Agent 63 Acute Heart Failure 63 Hepatocellular Carcinoma 63 ketolide antibiotic 63 novel VDA molecule 63 PD LID 63 Fondaparinux 63 Microplasmin 63 relapsed refractory 63 OncoVEX GM CSF 63 LUVENIQ 63 Trodusquemine MSI 63 subcutaneous formulation 63 Raptiva ® 63 CCX# 63 LY# [002] 63 TMC# [002] 63 CG# [003] 63 Azacitidine 63 Afatinib 63 Janus kinase 63 Novel Inhibitor 63 Fidaxomicin 63 Myelodysplastic Syndrome MDS 63 Nanobody 63 Statistically Significant 63 Tigecycline 63 IAP inhibitor 63 vascular disrupting agent 63 protein tyrosine phosphatase 1B 63 R lenalidomide 63 MEK inhibitor 63 Solazed ™ 63 vemurafenib 63 targeted radiotherapeutic 63 Vicinium TM 63 anti CD3 monoclonal 63 investigational pharmacologically unique 63 either acutely decompensated 63 anti TNF alpha 63 unique alkylating agent 63 Avanafil 63 SinuNase TM 63 YONDELIS R 63 SUTENT ® 63 ofatumumab 63 hepatitis C HCV 63 TRANSDUR ™ 63 nilotinib Tasigna 63 Fast Track Status 63 PRN FDA Approves 63 alkylating agent 63 human IgG1 monoclonal 63 MabCampath 63 IMC #B 63 Mycophenolate Mofetil 63 post herpetic neuralgia PHN 63 product BioThrax ® 63 luteinizing hormone releasing 63 albiglutide 63 Certolizumab 63 tocilizumab 63 TACI Ig 63 ritonavir boosted 63 basiliximab 63 orally bioavailable 63 Phase III Clinical Trials 63 5 HT3 antagonist 63 HuLuc# 63 Tipranavir 63 Kuvan R 63 dopamine partial agonist 63 Telaprevir 63 Trastuzumab DM1 63 non peptidic protease 63 Interferon Beta 63 relapsing remitting multiple sclerosis 63 IND Application 63 ZOLINZA 63 miconazole Lauriad ® 63 Placebo Controlled Trial 63 candidates Azedra 63 non metastatic osteosarcoma 63 Pegasys ® 63 INCB# [001] 63 EVIZON TM 63 SAR# [002] 63 octreotide implant 63 cilengitide 63 bevacizumab Avastin ® 63 Onco TCS 63 Pivotal Clinical Trial 63 Ceflatonin R 63 ORENCIA ® 63 cMET 63 FASLODEX 63 Medoxomil 63 Files Investigational 63 Allergic Rhinitis 63 Prospective Randomized 63 Therapeutic Vaccine 63 Actemra tocilizumab 63 Muraglitazar 63 Replacement Therapy 63 Paraplatin ® 63 Aptamer 63 selective antagonist 63 ribavirin Copegus ® 63 Novel Therapeutic 63 Clolar ® 63 Serdaxin 63 5 HT6 receptor 63 Novel Mechanism 63 Argatroban 63 Sprycel dasatinib 63 Topotecan 63 previously untreated follicular 63 ACTEMRA TM 63 mitogen activated ERK kinase 63 Herceptin trastuzumab 63 Allovectin 7 R 63 antibody MT# 63 Intravenous Formulation 63 pertuzumab 63 Testosterone Gel 63 lupus nephritis 63 rheumatoid arthritis RA psoriatic 63 Virulizin ® 63 Acute Ischemic Stroke 63 JAK1 63 Gleevec imatinib mesylate 63 Zolinza 63 docetaxel Taxotere R 63 Prodrug 63 Treatment Naïve 63 Seliciclib 63 markets Gelclair R 63 Leukemias 63 Zarnestra 63 Refractory Angina 63 Genentech Rituxan 63 BCG refractory carcinoma 63 thalidomide Thalomid 63 PEGylated 63 TO AVOID PREGNANCY WHILE 63 Fc fusion protein 63 IMiDs ® 63 LEUKINE 63 Certolizumab pegol 63 pegylated 63 5 HT4 63 MT# MEDI 63 Achieves Primary Endpoint 63 Naive Patients 63 Proxinium TM 63 Interferon beta 1a 63 Mg Usa 63 elotuzumab 63 Inhalation Solution 63 miconazole Lauriad R 63 LBH# 63 Lacosamide 63 metaglidasen 63 human monoclonal antibody 63 dual endothelin receptor antagonist 63 Tolvaptan 63 Cyclophosphamide 63 topoisomerase II inhibitor 63 trastuzumab Herceptin R 63 Placebo Controlled Study 63 Fluvastatin 63 itraconazole Sporanox 63 Valsartan 63 Racivir 63 Gefitinib 63 HSP# inhibitor 63 EGFR TKI 63 Prostate AdenoCarcinoma Treatment 63 lintuzumab SGN 63 Ilaris 63 Antitumor 63 Copegus R 63 Ticagrelor 63 Resistant Hypertension 63 ThermoDox R 63 posaconazole 63 huN# DM1 63 Capecitabine 63 Lixisenatide 63 brand ciclesonide HFA 63 HuMax TAC 63 Overactive Bladder 63 Double Blind Placebo 63 Brentuximab vedotin 63 forodesine 63 DXL# 63 Zorbtive TM 63 Submits NDA 63 INCB# [002] 63 Hypercholesterolemia 63 treat chronic sinusitis 63 TELINTRA 63 superficial bladder cancer 63 Tiotropium 63 Navelbine ® 63 agonistic human 63 Remicade infliximab 63 Treated Patients 63 T#I [002] 63 Teriflunomide 62 small molecule chemotherapeutic 62 Campath ® 62 myelodysplastic myeloproliferative diseases 62 TYGACIL 62 Omacetaxine mepesuccinate 62 stage IIIB 62 Vaprisol 62 alpha 2b 62 LEVADEX TM 62 Civacir 62 Deforolimus 62 Keryx Biopharma 62 BAY #-# 62 Antiangiogenic 62 Unresectable 62 Efficacy Results 62 calcineurin inhibitors 62 vitreoretinal disorders 62 anti EGFR antibody 62 investigational pan BCR 62 Etravirine 62 TYKERB 62 Roche Actemra 62 EZN 62 Crofelemer budesonide foam 62 metastatic renal cell carcinoma 62 Milnacipran 62 LHRH antagonists 62 adenosine injection 62 gastrointestinal stromal tumors 62 Dose Ranging 62 Cloretazine ® 62 Present Preclinical Data 62 Febuxostat 62 CTA# Injection 62 First Patient Treated 62 RNAi Therapeutics 62 Omalizumab 62 hA# 62 Zoraxel 62 Kuvan sapropterin dihydrochloride 62 Treatment Regimen 62 Adjunctive Therapy 62 Diabetic Nephropathy 62 acute peripheral arterial 62 Is Well Tolerated 62 Copegus ® 62 Phase #b/#a clinical 62 intranasal formulation 62 multiple myeloma MM 62 EGFr humanized monoclonal antibody 62 TLK# 62 GTC recombinant form 62 Newly Diagnosed Multiple Myeloma 62 diagnosed Ph + 62 Relapsed Multiple Myeloma 62 factor TNF receptor 62 Chronic Hepatitis B 62 TAFA# 62 Topline Results 62 GTC recombinant human 62 Factor Receptor 62 drug conjugate 62 JAK2 inhibitor 62 severe oral mucositis 62 Metastatic Prostate Cancer 62 ISTODAX ® 62 Cannabinor 62 Controlled Study 62 toenail onychomycosis 62 Systemic Delivery 62 Alferon N 62 Lupus Drug 62 baminercept 62 sorafenib Nexavar 62 Polymerase Inhibitor 62 Postmenopausal Osteoporosis 62 galiximab 62 Fodosine 62 Acute Exacerbations 62 Extended Release 62 diabetic neuropathic pain 62 R roscovitine CDK cyclin 62 Rasagiline 62 Follicular Lymphoma 62 Hypoactive Sexual Desire Disorder 62 Significantly Improved 62 Novel Compound 62 Belinostat 62 Anticalin R 62 ACZ# 62 dextromethorphan quinidine 62 phase IIb trial 62 Fludara ® 62 taxane derivative 62 includes TOLAMBA TM 62 chronic myeloid 62 Initiates Clinical Trial 62 volociximab 62 gefitinib Iressa 62 Preclinical Study 62 immunomodulator 62 Nucleoside 62 efalizumab 62 REMOXY POSIDUR ELADUR 62 JAK inhibitors 62 Noxafil 62 highly selective inhibitor 62 Bremelanotide 62 CEQ# 62 cinacalcet 62 Vitaxin 62 TRANSDUR ® 62 thymalfasin 62 Crohn disease CD 62 FLT3 62 Torisel 62 Therapeutic Antibody 62 Transdermal Patch 62 Protease Inhibitors 62 Adjuvant Therapy 62 Quinamed 62 Azedra 62 novel oral anticoagulant 62 PEGylated interferon 62 anthracycline derivative 62 Sodium oxybate 62 Mouse Model 62 BiTE ® 62 Demonstrates Potential 62 Potent Inhibitor 62 Antithrombin 62 CYP#A# CYP#D# 62 Human Monoclonal Antibody 62 KSP inhibitor 62 Fast Track Designation 62 Augment TM 62 EOquin TM 62 Ranibizumab 62 ceftazidime 62 cannabinor 62 chronic lymphocytic leukemia CLL 62 peptibody 62 IMiDs R 62 alefacept 62 Phase Ib study 62 IgG1 antibody 62 DU #b 62 Calcitonin 62 Lenocta TM 62 Hedgehog Pathway 62 ONGLYZA ™ 62 Combination Therapy 62 Ataluren 62 CDP# 62 Phase IIb trials 62 Homspera TM 62 Ulcerative Colitis 62 Dendritic Cells 62 chronic myeloid leukemia CML 62 Darusentan 62 Lambert Eaton Myasthenic 62 PROVENGE ® 62 Levoleucovorin 62 Oral Formulation 62 rufinamide 62 Oxytrex TM 62 Candesartan 62 use transdermal sumatriptan 62 Peginterferon Alfa 2a 62 Radioimmunotherapy 62 Serdaxin ® 62 Abbott HUMIRA 62 Neuvenge 62 VAPRISOL 62 RANK Ligand inhibitor 62 AKT inhibitor 62 Parathyroid Hormone 62 Initiates Phase 2b 62 Allovectin 7 ® 62 Begins Dosing 62 Solid Tumors 62 Estrogen Receptor 62 ZD# [001] 62 refractory gout 62 Darinaparsin 62 StemEx 62 mTOR mammalian target 62 Gemzar ® 62 Icatibant 62 Vascular Disrupting Agent 62 lenalidomide Revlimid R 62 selective kinase inhibitor 62 Bronchiectasis 62 epothilones 62 Diabetic Neuropathic Pain 62 Relapsing Multiple Sclerosis 62 Horizant ™ 62 Commences Phase 62 Phase Ib clinical trials 62 receptor blocker 62 vinca alkaloid 62 Anti Inflammatory Drug 62 plus DOXIL 62 Telaprevir VX 62 Octreolin 62 Advanced Colorectal Cancer 62 HQK 62 Demonstrates Potent 62 XmAb# 62 Prochymal TM 62 R#/MEM # 62 sapropterin dihydrochloride 62 CYP#A# substrate 62 rasagiline tablets 62 Alogliptin 62 Parkinson disease levodopa induced 62 Olaparib 62 imatinib Gleevec 62 APTIVUS r 62 Antigen Specific 62 proteasome inhibitors 62 EOquin 62 bevacizumab Avastin 62 Survival Benefit 62 Genasense R 62 humanized antibody 62 Velcade bortezomib 62 humanised monoclonal antibody 62 Orphan Status 62 Anticancer Agent 62 multicenter Phase III 62 phase III isavuconazole 62 MGCD# [001] 62 Ophena TM 62 nilotinib 62 ALK inhibitor 62 IMiDs ® compound 62 novel antibody therapeutics 62 telomerase therapeutic 62 Atripla combines 62 K ras mutations 62 FDA Orphan Drug 62 relapsed multiple myeloma 62 Neoadjuvant 62 Rifaximin 62 cutaneous T 62 DDP# 62 systemic fungal infections 62 PEG IFN 62 sunitinib Sutent 62 Demonstrated Significant 62 pegylated interferons 62 hypoxia inducible factor 62 recurrent metastatic ovarian cancer 62 Orphan Drug 62 bosutinib 62 otelixizumab 61 evaluating picoplatin 61 Completes Patient Enrolment 61 Diabetic Neuropathy 61 Hydroxyurea 61 pan histone deacetylase 61 Biogen Genentech

Back to home page